Abbott → AbbVie: One of the Most Successful Spin-offs Ever

A Healthy Company—Why Cut Yourself in Two?

The last piece, GE, was cornered by the empire's complexity and the dynamite of GE Capital, and had no choice but to break up. That was "the split after a crisis."

Abbott's story is entirely different. When it announced the spin-off in 2011 and completed it in early 2013, Abbott was a soundly run, richly profitable, century-old healthcare giant with no immediate crisis at all. It was not forced to split; it chose to. That is exactly what makes it precious—it demonstrated the highest form of "the split": not amputation to survive, but elective surgery performed while healthy, so two organs could each grow stronger.

To understand this decision, you first have to understand that inside Abbott lived two souls of completely opposite temperament.

One Becomes Two: The 2013 Operation

In January 2013, Abbott formally split in two. A century-old brand cleanly cleaved into two listed companies:

Miles White stayed on to run Abbott; Richard Gonzalez became AbbVie's CEO. From that point the two companies went their separate ways—and the story that followed became one of the business schools' favorite case studies of a win-win spin-off.

Why Did It Have to Split? Two Kinds of Risk Need Two Kinds of Shareholders

On the surface, medical devices and pharmaceuticals are both "healthcare," so it seems reasonable to keep them together. But from a capital-allocation standpoint, they are two utterly different businesses that attract two completely different kinds of shareholders.

Those who buy defensive healthcare like Abbott are conservative investors seeking "stability, low volatility, and predictable dividends"—they want the reassurance of resilience across the cycle. Those who buy pure pharma like AbbVie are investors willing to bear the high risk of "patent cliffs and clinical failures" in exchange for the high reward of "a blockbuster breakout"—they want growth and the bet.

AbbVie's Blessing and Curse: The Blockbuster King Humira

The Humira that AbbVie took with it was no ordinary drug—it was one of the best-selling medicines in human history. In 2021, Humira posted full-year sales of about US$20.7 billion, sitting firmly atop the global sales charts as the king of drugs, and for years it contributed the majority of AbbVie's revenue and profit.

But that blessing concealed the curse every pharmaceutical company fears most—the patent cliff. Once a drug's patent expires, biosimilars flood in and price and market share can collapse off a cliff. At the time of the split, the market's biggest worry was exactly this: AbbVie was staking its entire fortune on a drug nearing patent expiry—wasn't that just spinning off a time bomb?

Over the following decade, AbbVie proved that what the spin-off gave it was precisely what it needed to defuse that bomb—freedom.

Freedom After Independence: How AbbVie Defused Its Own Bomb

The Mother Took Flight Too: Abbott's Defensive Compounding

In spin-off stories, a subsidiary soaring is hardly rare; what is genuinely rare is this—the parent lived better too.

Free of the Humira patent-cliff cloud, Abbott could finally be repriced by the market as "pure defensive, diversified healthcare." It bore fruit across several tracks: continuous glucose monitoring (FreeStyle Libre) became a global star product in diabetes management; structural-heart devices; and in-vitro diagnostics—the last of which exploded amid COVID-testing demand in 2020–2021. Abbott sits firmly among the "dividend aristocrats," raising its dividend year after year, and became conservative investors' favorite healthcare income stock.

The same set of assets that dragged each other down and was discounted by the market before the split was, after the split, rediscovered by the right shareholders at the right valuation. This is the cleanest demonstration of the focus premium.

Both Sides Win: The Purest Proof of the Focus Premium

The success or failure of a spin-off is ultimately spoken by the stock price. The reason Abbott → AbbVie is hailed as "one of the most successful spin-offs ever" is precisely that it pulled off the hardest thing in any spin-off—a win for both parent and child. As of early 2020, post-split Abbott was up about 184% and AbbVie about 158%, both far outpacing the broad market, and both maintained their status as dividend aristocrats.

Note: figures are approximate, in USD, and some are drawn from annual reports of various years; stock-return figures are as of the cited dates. Past performance does not indicate future results.

GE vs Abbott: The Forced Split and the Proactive Split

Put the first two pieces of this series side by side, and the two grades of "the split" come into clear view.

GE was a forced split—it only resolved to break up once the conglomerate discount and its financial dynamite had pushed the company to the edge of the cliff. The price was a lost two decades. Abbott was a proactive split—with no crisis at hand, it clearly saw that the two souls inside it should part ways, and performed the surgery in advance.

The Lesson for Taiwan: Don't Wait for a Crisis to Think About Splitting

Does Taiwan have an example of "splitting proactively while healthy"? Yes—UMC's "design-house fleet"

Taiwan's most classic case of "splitting proactively while healthy + internal entrepreneurship" is UMC's (2303) "design-house fleet." In 1995, after Robert Tsao transformed UMC from an integrated device manufacturer (IDM) into a pure foundry, he made a decision that looked counterintuitive at the time—rather than keeping its internal IC design teams as in-house cash cows, he spun them off one by one, listed them independently, and gave engineers equity and a stage to build their own ventures, cultivating an entire design army including MediaTek (2454), Novatek (3034), Faraday (3035), ITE Tech, and Pixart.

This split did two things right at once, mapping neatly onto the two themes of this series:

Up Next: When a Spin-off Is Meant to Let the Child Outgrow the Parent

GE was a post-crisis split, Abbott a proactive split while healthy. In the next piece, we look at an even more dramatic script—a company's spun-off "child" that not only became independent but went on to surpass the "parent" itself.

That is the story of eBay and PayPal. See you in the next piece.

Post-Spin-off Scorecard: Abbott → AbbVie

Using the six questions from the introduction, here's the overall verdict on this spin-off:

Overall verdict: a win for both parent and child, passing all six—the best example of a "proactive split while healthy."